1 1

Medical Education Hub

Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

€20,00 EUR
€20,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.

Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

Penn Medicine CV Pharmacologic Risk Reduction
Include: 13 videos + 16 pdfs, size: 3.02 GB
Date & Location

Friday, September 30, 2022, 7:45 AM – 2:00 PM, Virtual, Philadelphia, PA

Course Overview

CVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new guidelines for hypertension, DM and CKD and will discuss the advances in pharmacotherapeutics in these fields.

Target Audience
Penn Medicine CV Pharmacologic Risk Reduction
Specialties – FAMILY MEDICINE, FAMILY MEDICINE – Geriatric Medicine, INTERNAL MEDICINE, INTERNAL MEDICINE – Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE – Clinical Cardiac Electrophysiology, INTERNAL MEDICINE – Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE – Geriatric Medicine, INTERNAL MEDICINE – Interventional Cardiology, INTERNAL MEDICINE – Nephrology, INTERNAL MEDICINE – Sports Medicine, OBSTETRICS AND GYNECOLOGY, OBSTETRICS AND GYNECOLOGY – Maternal and Fetal Medicine, PREVENTIVE MEDICINE – Clinical Informatics, PUBLIC HEALTH AND GENERAL PREVENTIVE MEDICINE
Learning Objectives

After completing this activity, participants should be able to:

  1. Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
  2. Identify appropriate blood pressure goals and management in several special patient populations
  3. Review the controversies regarding the appropriate treatment of and management of pregnant patients at risk for CVD.
  4. Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia in young patients.
  5. Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention

 

 Topics:

  • BP Goals and Use of Thiazides in Advanced CKD.mp4
    BP Goals and Use of Thiazides in Advanced CKD.pdf
    BP Goals Management in Elderly (STEP Trial and SPRINT).mp4
    BP Goals Management in Elderly (STEP Trial and SPRINT).pdf
    BP22_Brochure_v4.pdf
    Cholesterol.mp4
    Cholesterol.pdf
    Clinical Case Discussion FOUNDATIONS- REFRESHER OF THE CURRENT GUIDELINES.pdf
    Clinical Case Discussion SPECIAL POPULATIONS.pdf
    DM Weight loss.mp4
    DM Weight loss.pdf
    Hypertension.mp4
    Hypertension.pdf
    Lipid Management and Risk Assessment in Younger Patients.mp4
    Lipid Management and Risk Assessment in Younger Patients.pdf
    New Agents in Lipid Management.mp4
    New Agents in Lipid Management.pdf
    Non-steroidal MRAs in HTN, DM2, and CKD.mp4
    Non-steroidal MRAs in HTN, DM2, and CKD.pdf
    Peripartum CV Risk Reduction.mp4
    Peripartum CV Risk Reduction.pdf
    Polypill – Quad Study Combo Therapy for BP and Lipids.mp4
    Polypill – Quad Study Combo Therapy for BP and Lipids.pdf
    Population-Wide Effects and Local Public Health Efforts of Sodium Reduction.mp4
    Population-Wide Effects and Local Public Health Efforts of Sodium Reduction.pdf
    Update in Renal Denervation.mp4
    Update in Renal Denervation.pdf
    Weight Loss Strategies in Highly Comorbid Patients.mp4
    Weight Loss Strategies in Highly Comorbid Patients.pdf
View full details